AdaptHealth Q4 revenue beats expectations, loss bigger than expected

Reuters
02/24
AdaptHealth Q4 revenue beats expectations, loss bigger than expected

Overview

  • Healthcare-at-home provider's Q4 revenue beat analyst expectations

  • Q4 operating loss and pretax loss wider than analyst expectations

  • Company expanded footprint by acquiring HME provider in Hawaii

Outlook

  • AdaptHealth forecasts 2026 net revenue between $3.44 bln and $3.51 bln

  • Company expects 2026 adjusted EBITDA of $680 mln to $730 mln

  • AdaptHealth projects 2026 free cash flow of $175 mln to $225 mln

Result Drivers

  • PATIENT GROWTH - AdaptHealth set new patient census records in Sleep Health, Respiratory Health, and Wellness at Home

  • GEOGRAPHIC EXPANSION - Acquired a leading HME provider in Hawaii, expanding the company's footprint to its 48th state

  • DIGITAL ENGAGEMENT - More than doubled myApp users to 327,300, enhancing digital patient engagement

Company press release: ID:nBw8nk0Wma

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$846.29 mln

$831.61 mln (8 Analysts)

Q4 Net Income

-$101.54 mln

Q4 Operating Income

Miss

-$73.28 mln

$89.60 mln (8 Analysts)

Q4 Pretax Profit

Miss

-$97.99 mln

$65.06 mln (7 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Adapthealth Corp is $13.00, about 26.3% above its February 23 closing price of $10.29

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10